(Q44373197)

2 December 2017

title

Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma (English)

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

17 October 2022

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

17 October 2022

author name string

H. Thomas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627371

17 October 2022

C. Barton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627371

17 October 2022

A. Saini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627371

17 October 2022

A. Dalgleish

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627371

17 October 2022

J. Waxman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1627371

17 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1627371

17 October 2022

publication date

1 January 1992

1 reference

full work available at URL

2 December 2017

https://api.elsevier.com/content/article/PII:0959804992904528?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

https://api.elsevier.com/content/article/PII:0959804992904528?httpAccept=text/plain

17 October 2022

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

European Journal of Cancer

17 October 2022

published in

1 reference

2 December 2017

volume

28A

1 reference

2 December 2017

issue

6-7

1 reference

2 December 2017

page(s)

1047-1049

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

2 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

17 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin

17 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

Is the outlook changing for patients with renal cell cancer?

17 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

17 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

17 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma

17 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience

17 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0959-8049(92)90452-8

17 October 2022

Identifiers

1 reference

2 December 2017

1 reference